Logotipo do repositório
 

Publicação:
Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?

dc.contributor.authorLemes, Luciana Rodino
dc.contributor.authorMelo, Daniel Fernandes
dc.contributor.authorde Oliveira, Daniele Sguissardi
dc.contributor.authorde La-Rocque, Marcella
dc.contributor.authorZompero, Camila
dc.contributor.authorRamos, Paulo Müller [UNESP]
dc.contributor.institutionUniversity of State of Rio de Janeiro
dc.contributor.institutionBonsucesso Federal Hospital
dc.contributor.institutionBalneario Camboriú
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2020-12-12T02:14:55Z
dc.date.available2020-12-12T02:14:55Z
dc.date.issued2020-01-01
dc.description.abstractMinoxidil is a strong arterial vasodilator, first introduced as an antihypertensive medication. In dermatology, topical minoxidil (TMX) has been used for many types of alopecia. TMX is not FDA-approved in patients under 18 years old and there are no guidelines for its pediatric use. Low-dose oral minoxidil (OMX) has been used off-label for hair loss treatment in adults expecting to achieve better therapeutic compliance and greater clinical efficacy. However, little is known about TMX and OMX in pediatric population. the literature presented on TMX and OMX in children to date was reviewed. The terms “minoxidil”, “child”, “children”, “childhood”, and “infant” were used to perform a literature search in MEDLINE through PubMed. The search was limited to articles about humans and available in English. While 25 relevant articles were selected, duplicate titles were excluded. This article pointed out the use of minoxidil in several pediatric hair diseases. Even when used topically, dermatologists should be aware of potential risks of systemic absorption. In particular situations, OMX in very low doses may be considered. To date, there are no guidelines regarding the ideal dose or minimum age for using the drug topically or systemically.en
dc.description.affiliationDepartment of Dermatology University of State of Rio de Janeiro
dc.description.affiliationDepartment of Dermatology Bonsucesso Federal Hospital
dc.description.affiliationPrivate Practice Balneario Camboriú
dc.description.affiliationDepartment of Dermatology São Paulo State University—UNESP
dc.description.affiliationUnespDepartment of Dermatology São Paulo State University—UNESP
dc.identifierhttp://dx.doi.org/10.1111/dth.13950
dc.identifier.citationDermatologic Therapy.
dc.identifier.doi10.1111/dth.13950
dc.identifier.issn1529-8019
dc.identifier.issn1396-0296
dc.identifier.scopus2-s2.0-85087812229
dc.identifier.urihttp://hdl.handle.net/11449/200744
dc.language.isoeng
dc.relation.ispartofDermatologic Therapy
dc.sourceScopus
dc.subjectalopecia
dc.subjectchildhood
dc.subjectchildren
dc.subjecthair disorders
dc.subjectminoxidil
dc.subjectoral minoxidil
dc.subjecttopical minoxidil
dc.titleTopical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?en
dc.typeResenha
dspace.entity.typePublication
unesp.author.orcid0000-0002-9068-3225[1]
unesp.author.orcid0000-0002-8807-2556[2]
unesp.author.orcid0000-0002-2124-4536[3]
unesp.author.orcid0000-0002-9937-6256[4]
unesp.author.orcid0000-0001-8853-4776[5]
unesp.author.orcid0000-0002-1561-414X[6]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentDermatologia e Radioterapia - FMBpt

Arquivos